Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects

Next Previous
Trial Profile

An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6648671 (Primary) ; Midazolam
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 17 Jul 2019 PKPD model was developed to characterize the differential effects of PF 06648671 on the various CSF species in healthy humans using data from three phase I studies (NCT02316756, NCT02440100 and NCT02407353 ); results published in the Clinical Pharmacology and Therapeutics
  • 20 Jul 2017 Results of 3 phase 1 studies assessing plasma exposure and cerebrospinal fluid response relationship in healthy subjects, presented at the Alzheimer's Association International Conference 2017.
  • 08 Nov 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top